Holen Sie sich die Stockscreener-App
80.19
0.36%
0.29
Vorhandelsmarkt:
81.16
0.97
+1.21%
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt AZN?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$79.90
Offen:
$79.86
24-Stunden-Volumen:
2.99M
Relative Volume:
0.68
Marktkapitalisierung:
$248.70B
Einnahmen:
$56.53B
Nettoeinkommen (Verlust:
$8.32B
KGV:
29.92
EPS:
2.6798
Netto-Cashflow:
$8.49B
1W Leistung:
+0.17%
1M Leistung:
+8.44%
6M Leistung:
+5.22%
1J Leistung:
-8.48%
1-Tages-Spanne:
$79.43
$80.59
1-Wochen-Bereich:
$79.35
$80.59
52-Wochen-Spanne:
$61.24
$87.25
Astrazeneca PLC Stock (AZN) Company Profile
Firmenname
Astrazeneca PLC
Sektor
Branche
Telefon
44 20 3749 5000
Adresse
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Vergleichen Sie AZN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
80.19 | 247.73B | 56.53B | 8.32B | 8.49B | 2.6798 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-15 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2025-02-13 | Hochstufung | UBS | Neutral → Buy |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-20 | Hochstufung | UBS | Sell → Neutral |
| 2024-11-06 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-09-13 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-04-16 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-02-08 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-16 | Fortgesetzt | UBS | Sell |
| 2024-01-03 | Herabstufung | Jefferies | Buy → Hold |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-09-25 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-12 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-05 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-04-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-09-15 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | Hochstufung | Argus | Hold → Buy |
| 2022-06-14 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-11 | Hochstufung | DZ Bank | Sell → Hold |
| 2021-12-07 | Herabstufung | Jefferies | Buy → Hold |
| 2021-08-12 | Fortgesetzt | JP Morgan | Overweight |
| 2021-04-12 | Herabstufung | Argus | Buy → Hold |
| 2021-03-16 | Hochstufung | Jefferies | Hold → Buy |
| 2021-02-25 | Hochstufung | UBS | Neutral → Buy |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-12-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | Hochstufung | UBS | Sell → Neutral |
| 2020-11-11 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2019-11-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-10-25 | Hochstufung | Liberum | Hold → Buy |
| 2019-04-02 | Herabstufung | UBS | Neutral → Sell |
| 2019-02-05 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2019-01-25 | Hochstufung | Shore Capital | Hold → Buy |
| 2018-12-11 | Fortgesetzt | Jefferies | Hold |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-08-16 | Herabstufung | Jefferies | Buy → Hold |
| 2018-03-19 | Hochstufung | Jefferies | Hold → Buy |
| 2018-02-06 | Bestätigt | Leerink Partners | Mkt Perform |
| 2018-02-05 | Bestätigt | Bernstein | Outperform |
| 2018-01-18 | Bestätigt | Leerink Partners | Mkt Perform |
| 2017-12-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-10-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | Hochstufung | Bernstein | Mkt Perform → Outperform |
Alle ansehen
Astrazeneca PLC Aktie (AZN) Neueste Nachrichten
Will AstraZeneca PLC Depositary Receipt price bounce be sustainableRisk Management & Daily Risk Controlled Trade Plans - Newser
Just over £119 now, AstraZeneca’s share price looks cheap to me anywhere under £220.91 - uk.finance.yahoo.com
Can machine learning forecast AstraZeneca PLC Depositary Receipt recoveryWeekly Investment Report & Expert Curated Trade Ideas - Newser
What technical models suggest about AstraZeneca PLC Depositary Receipt’s comeback - Newser
Is AstraZeneca PLC Depositary Receipt a defensive stock2025 Volatility Report & Free Expert Approved Momentum Trade Ideas - خودرو بانک
Mineralys surges after late-stage trial data AstraZeneca’s blood pressure drug - Seeking Alpha
What momentum shifts mean for AstraZeneca PLC Depositary ReceiptTrade Risk Assessment & Smart Allocation Stock Tips - Newser
What institutional flow reveals about AstraZeneca PLC Depositary ReceiptEntry Point & Stock Market Timing Techniques - Newser
What MACD and RSI say about AstraZeneca PLC Depositary ReceiptShare Buyback & Verified Momentum Stock Watchlist - Newser
What are AstraZeneca PLC Depositary Receipt’s recent SEC filings showingDividend Hike & AI Based Trade Execution Alerts - خودرو بانک
Detecting price anomalies in AstraZeneca PLC Depositary Receipt with AITrend Reversal & Expert Approved Momentum Ideas - Newser
Verdion signs AstraZeneca to Stockholm logistics park - Green Street News
AstraZeneca's Latest Drug Offers Hope For Millions Battling Hard-To-Control Blood Pressure - Yahoo Finance
FibroGen Completes Sale of Chinese Subsidiary to AstraZeneca - MarketScreener
AstraZeneca reports total voting rights of 1.55 billion ordinary shares - Investing.com
AstraZeneca: Buy This Pharma Star Now For Upside Potential - Seeking Alpha
What’s AstraZeneca PLC Depositary Receipt’s historical returnJuly 2025 Trends & Stepwise Entry and Exit Trade Signals - خودرو بانک
Can AstraZeneca PLC Depositary Receipt deliver alphaJuly 2025 Analyst Calls & Technical Pattern Based Buy Signals - خودرو بانک
Real time scanner hits for AstraZeneca PLC Depositary Receipt explainedJuly 2025 Big Picture & Expert Curated Trade Setup Alerts - Newser
AstraZeneca Announces Current Share Capital and Voting Rights - TipRanks
AstraZeneca’s baxdrostat shows promise in Phase III hypertension trial - Clinical Trials Arena
Published on: 2025-09-01 16:47:49 - خودرو بانک
Can trapped investors hope for a rebound in AstraZeneca PLC Depositary ReceiptMarket Activity Summary & Technical Pattern Based Buy Signals - Newser
AstraZeneca Shares (LON:AZN) Higher: Strong Baxdrostat Data - AskTraders.com
AstraZeneca to seek approval for new drug which could deliver $5 billion annual sales, 1 Sep 2025 11:43 - Shares Magazine
What candlestick patterns are forming on AstraZeneca PLC Depositary ReceiptPortfolio Return Report & High Yield Equity Trading Tips - Newser
After this weekend’s news, is it time to look again at the AstraZeneca share price? - MSN
Signal strength of AstraZeneca PLC Depositary Receipt stock in tech scannersEarnings Recap Report & Long-Term Safe Investment Ideas - Newser
Multi asset correlation models including AstraZeneca PLC Depositary ReceiptPortfolio Performance Report & Reliable Entry Point Trade Alerts - Newser
How to recover losses in AstraZeneca PLC Depositary Receipt stockJuly 2025 Reactions & Community Supported Trade Ideas - Newser
AstraZeneca's Hypertension Drug Lowers Blood Pressure in 'Meaningful, Sustained' Manner - MarketScreener
AstraZeneca | Pharmaceuticals, Vaccines, & Facts - Britannica
Technical analysis overview for AstraZeneca PLC Depositary Receipt stock2025 Volume Leaders & Technical Confirmation Trade Alerts - Newser
Shareholders that lost money on AstraZeneca PLC (AZN) should contact Levi & Korsinsky about pending Class ActionAZN - ACCESS Newswire
AstraZeneca’s New Study on T-DXd Offers Hope for HER2-Positive Tumor Patients - MSN
AstraZeneca is said to seek approval for antihypertensive this year - Seeking Alpha
AstraZeneca Faces Close Race With Mineralys After Phase III Hypertension Readout - insights.citeline.com
15.7mmHg Blood Pressure Reduction: AstraZeneca's Novel Drug Shows Breakthrough in Treatment-Resistant HTN - Stock Titan
AstraZeneca to seek approval for blood pressure drug by year-end - MarketScreener
AstraZeneca PLC Depositary Receipt Included in Top Momentum ScanJuly 2025 Update & Technical Pattern Based Signals - beatles.ru
What does recent volatility data suggest for AstraZeneca PLC Depositary Receipt2025 Trade Ideas & Technical Buy Zone Confirmations - Newser
Using Ichimoku Cloud for AstraZeneca PLC Depositary Receipt technicalsWeekly Trade Summary & Free AI Powered Buy and Sell Recommendations - Newser
Is it time to cut losses on AstraZeneca PLC Depositary ReceiptWeekly Trade Report & Safe Capital Growth Plans - Newser
SGLT2 Inhibitors Market to Hit USD 29.73 Billion by 2032, Driven by Expanding Diabetes Management and Cardiovascular Benefits – SNS Insider - GlobeNewswire Inc.
AstraZeneca PLC (AZN) Oncology Sales Hit $12B in H1 2025 - MSN
Finanzdaten der Astrazeneca PLC-Aktie (AZN)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):